leisure time -WSS

leisure time

author：knowledge 2025-09-27 12:48:01 - browse：69

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Why doctors need education on FDA device approval process

knowledge

WSS

Hospitals need to get ahead of regulations on climate change

eGenesis tests gene

My yearlong odyssey to get my son’s ADHD medication covered

Medicare Advantage today, explained in one chart

Bird flu makes raw milk dangerous to consume, mouse study finds

FDA clears AI tool for detecting skin cancer

leisure time

leisure time

hotspot

Psychedelics group wrestles with new pharma identity

Why doctors need education on FDA device approval process

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Bird flu makes raw milk dangerous to consume, mouse study finds

Medicare proposal to cover medical devices draws a mixed reaction

Hospitals need to get ahead of regulations on climate change

Anesthesiologist group: stop taking Ozempic before surgery

Decentralized clinical trials need collaboration to achieve wider use

Medical records are filled with copy

Medical students need to learn the potent medicine of empathy

hotspot

How digital therapeutics firms are pivoting after Pear's bankruptcy

The world needs the new pandemic treaty

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Protect nursing home residents from future pandemics

focus

Independent physicians launch a new lobbying group

explore

knowledge

leisure time

focus